Webinar: Pharmacovigilance

New European pharmacovigilance rules take full effect on 12 February 2026, just weeks before Australia's Therapeutic Goods Administration begins operating under its updated compliance framework for 2026 and 2027. Pharmacovigilance—the science and activities involved in detecting, assessing, understanding and preventing adverse effects or other medicine-related problems—now sits at the centre of regulatory pressure worldwide.

Adverse event reports have surged. The US Food and Drug Administration alone processes more than 2.1 million individual case safety reports each year, three times the volume seen in 2010. Faster approvals for complex therapies such as gene treatments and personalised medicines mean rarer side effects often surface only after millions of patients have used the product.

In Australia every sponsor of a medicine on the Australian Register of Therapeutic Goods must run a continuous safety monitoring system. This includes collecting reports from health professionals and patients, evaluating signals, maintaining risk management plans and submitting periodic safety update reports. The TGA publishes monthly lists of product information changes that flow directly from this work, ensuring prescribers and consumers receive timely warnings.

The European changes tighten obligations across the board. From mid-February companies must conduct risk-based audits of all pharmacovigilance activities, including those performed by subcontractors, with explicit contract clauses on data exchange and inspection rights. Periodic safety update reports must now include evidence that risk-minimisation measures actually work. Signal validation responsibility shifts more to regulators, freeing manufacturers but demanding higher-quality data flows.

Australia's TGA has signalled increased enforcement on artificial intelligence tools used in safety monitoring. Consultation outcomes released in July 2025 highlighted gaps around adaptive AI and open datasets. The agency has committed $39.9 million over five years to safe and responsible AI initiatives and will treat certain AI systems as regulated medical devices if they meet the criteria. Sponsors must document data provenance and engage early or risk compliance action throughout 2025-2026.

The TGA's new five compliance principles, effective from 1 January 2026, emphasise safeguarding therapeutic goods against unsafe products, leveraging digital monitoring capabilities and protecting vulnerable groups. Priorities include substandard and falsified medicines as well as listed-medicine advertising, with quarterly reviews allowing rapid shifts in focus. Digital risks, including AI-generated misinformation, now sit at the core of enforcement strategy.

Patients bear the direct consequences. Undetected safety signals can lead to hospitalisations, long-term harm or, in extreme cases, deaths that might have been prevented. Pharmaceutical companies face product withdrawals that cost hundreds of millions, regulatory fines and lasting reputational damage. Health systems lose confidence when trusted medicines prove riskier than expected.

Global harmonisation through the International Council for Harmonisation helps reduce duplication, yet local requirements still demand tailored systems. With real-world evidence growing in importance and artificial intelligence reshaping signal detection, pharmacovigilance has moved from a back-office function to a strategic necessity that determines whether innovative treatments reach patients safely or stall under regulatory scrutiny.